BLZ945 is an inhibitor of the CSF-1R kinase receptor; it exhibits immunostimulatory and anticancer chemotherapeutic activities and prevents skeletal metastasis of diseases. BLZ945 prevents turnover of tumor-associated macrophages and increases CD8+ T cell levels, limiting tumor growth in animal models of mammary carcinogenesis.
| Cas No. | 953769-46-5 |
|---|---|
| Purity | ≥95% |
| Formula | C20H22N4O3S |
| Formula Wt. | 398.48 |
| Chemical Name | 4-[(2-{[(1R,2R)-2-Hydroxycyclohexyl]amino}-1,3-benzothiazol-6-yl)oxy]-N-methyl-2-pyridinecarboxamide |
| IUPAC Name | 4-[(2-{[(1R,2R)-2-Hydroxycyclohexyl]amino}-1,3-benzothiazol-6-yl)oxy]-N-methyl-2-pyridinecarboxamide |
| Synonym | BLZ945 |
| Solubility | Soluble in DMSO. Slightly soluble in ethanol. Insoluble in water. |
| Appearance | Pale yellow solid. |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Krauser JA, Jin Y, Walles M, et al. Phenotypic and metabolic investigation of a CSF-1R kinase receptor inhibitor (BLZ945) and its pharmacologically active metabolite. Xenobiotica. 2015 Feb;45(2):107-23. PMID: 25180976.
Strachan DC, Ruffell B, Oei Y, et al. CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8+ T cells. Oncoimmunology. 2013 Dec 1;2(12):e26968. PMID: 24498562.
